German Spondyloarthritis Inception Cohort

NCT01277419 · tracked via the Priya Life Science Germany tracker

Sponsor

Charite University, Berlin, Germany

Phase

Observational

Started

2000-07

Last updated

2021-10-12

Condition(s) studied

Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)Non-radiographic Axial Spondyloarthritis (Nr-axSpA)Axial Psoriatic Arthritis (axPsA)Acute Anterior Uveitis (AAU)Crohn Disease (CD)Ulcerative Colitis (UC)

Study summary

The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Main inclusion Criteria: * Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis. * Patients with definite diagnosis of Crohn's disease. * Patients with definite diagnosis of acute anterior uveitis. * Patients with definite diagnosis of psoriatic arthritis with axial involvement.

Trial sites (1)

Facility	City	Region	Status
Charité - Universitätsmedizin Berlin	Berlin	Germany	Recruiting

More Charite University, Berlin, Germany trials in Germany

Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE) Starting soon

Berlin-Brandenburg Pregnancy Cohort Recruiting

Prospective Validation Study of the CD8+TEMRA Cells As a Prognostic Biomarker of Healing Outcome After Fracture Recruiting

Quality Contract: Prevention of Postoperative Delirium in the Care of Older Patients (QV-POD-2) Recruiting

Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer Starting soon

Other trials for the same condition

AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis Recruiting

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis Recruiting

Wild Blueberries in Colitis Recruiting

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01277419 on ClinicalTrials.gov ↗ ← All trials in Germany